• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Variable response to long-term 1alpha-hydroxycholecalciferol in haemodialysis osteodystrophy.

作者信息

Pierides A M, Ellis H A, Simpson W, Dewar J H, Ward M K, Kerr D N

出版信息

Lancet. 1976 May 22;1(7969):1092-5. doi: 10.1016/s0140-6736(76)90061-1.

DOI:10.1016/s0140-6736(76)90061-1
PMID:57505
Abstract

Ten uraemic patients on regular haemodialysis were treated with 1alpha-hydroxycholecalciferol (1alpha-H.C.C.) for 5 to 14 months. Five patients who had histological osteitis fibrosa with or without osteomalacia responded well, with resolution of musculoskeletal pain, return of raised serum-alkaline-phosphatase concentrations to normal, resolution of radiological subperiosteal erosions, and improvement in histological signs of osteitis fibrosa and osteomalacia. In these patients 1alpha-H.C.C. proved a safe and effective drug. Five other patients did not improve. Characteristically these patients started with moderately severe histological osteomalacia and minimal, if any, osteitis fibrosa. Proximal myopathy was a prominent symptom and serum-alkaline-phosphatase was normal in four of them. Treatment with 1alpha-H.C.C. resulted in early troublesome hypercalcaemia, and repeat bone histology 5--11 months later showed no improvement. It is suggested that in these patients lack of 1,25-dihydroxycholecalciferol may not have been wholly responsible for the observed osteomalacia, hence 1alpha-H.C.C. alone was ineffective. Phosphate depeltion may have been an important contributing factor.

摘要

相似文献

1
Variable response to long-term 1alpha-hydroxycholecalciferol in haemodialysis osteodystrophy.
Lancet. 1976 May 22;1(7969):1092-5. doi: 10.1016/s0140-6736(76)90061-1.
2
Histopathology of renal osteodystrophy with particular reference to the effects of 1alpha-hydroxyvitamin D3 in patients treated by long-term haemodialysis.肾性骨营养不良的组织病理学,特别提及长期血液透析患者中1α-羟维生素D3的作用
Clin Endocrinol (Oxf). 1977 Dec;7 Suppl:31s-38s. doi: 10.1111/j.1365-2265.1977.tb03359.x.
3
The effect of 1alpha-hydroxyvitamin D3 in pre-dialysis renal bone disease.
Clin Endocrinol (Oxf). 1977 Dec;7 Suppl:109s-116s. doi: 10.1111/j.1365-2265.1977.tb03370.x.
4
Long-term effects of small doses of 1,25-dihydroxycholecalciferol in renal osteodystrophy.小剂量1,25 - 二羟胆钙化醇对肾性骨营养不良的长期影响。
Lancet. 1978 Mar 25;1(8065):629-32. doi: 10.1016/s0140-6736(78)91137-6.
5
Experience with 1,25-dihydroxycholecalciferol therapy in undergoing hemodialysis patients with progressive vitamin D2-treated osteodystrophy.
Am J Med. 1979 Oct;67(4):583-9. doi: 10.1016/0002-9343(79)90238-9.
6
Factors influencing the response to 1alpha-hydroxyvitamin D3 in patients with renal bone disease.
Clin Endocrinol (Oxf). 1977 Dec;7 Suppl:51s-57s. doi: 10.1111/j.1365-2265.1977.tb03362.x.
7
1 alpha-hydroxycholecalciferol in hemodialysis renal osteodystrophy. Adverse effects of anticonvulsant therapy.血液透析肾性骨营养不良中的1α-羟基胆钙化醇。抗惊厥治疗的不良反应。
Clin Nephrol. 1976 Apr;3(2):189-96.
8
Hemodialysis bone disease: correlation between clinical, histologic, and other findings.
Kidney Int. 1978 Jul;14(1):68-73. doi: 10.1038/ki.1978.90.
9
Osteomalacia in patients with chronic renal failure before dialysis or transplantation.
Q J Med. 1983 Summer;52(207):332-48.
10
Clinical effects of 1,25-dihydroxyvitamin D3 in uremic patients with overt osteodystrophy.
Contrib Nephrol. 1980;18:29-41. doi: 10.1159/000403271.

引用本文的文献

1
Serum concentrations of 24,25-dihydroxy vitamin D in different degrees of chronic renal failure.不同程度慢性肾衰竭患者血清24,25-二羟维生素D的浓度
Br Med J. 1980 Sep 13;281(6242):712-3. doi: 10.1136/bmj.281.6242.712.
2
Pharmacology and therapeutic use of vitamin D and its analogues.维生素D及其类似物的药理学与治疗用途。
Drugs. 1981 Apr;21(4):241-56. doi: 10.2165/00003495-198121040-00001.
3
Prediction of postdialysis hypophosphataemia.透析后低磷血症的预测
Br Med J. 1977 Oct 22;2(6094):1060-1. doi: 10.1136/bmj.2.6094.1060-a.
4
Treatment of renal osteodystrophy with 1alpha-hydroxycholecalciferol (1alpha-OH-D3) in conjunction with a high dialysate calcium.
Calcif Tissue Res. 1977 May;22 Suppl:94-100. doi: 10.1007/BF02064047.
5
1alpha-Hydroxycholecalciferol in children with renal osteodystrophy.
Calcif Tissue Res. 1977 May;22 Suppl:371-5. doi: 10.1007/BF02064103.
6
1alpha-Hydroxycholecalciferol in renal osteodystrophy.
Calcif Tissue Res. 1977 May;22 Suppl:105-11. doi: 10.1007/BF02064049.
7
1-alpha-hydroxycholecalciferol for renal osteodystrophy.1-α-羟胆钙化醇用于肾性骨营养不良
Br Med J. 1977 Sep 17;2(6089):721-3. doi: 10.1136/bmj.2.6089.721.
8
Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol.未接受透析治疗的青少年肾性骨营养不良。1α-羟胆钙化醇的长期治疗。
Arch Dis Child. 1977 Jun;52(6):473-81. doi: 10.1136/adc.52.6.473.
9
1,25-dihydroxycholecalciferol in renal osteodystrophy. Epiphysiolysis--anticonvulsant therapy.1,25-二羟胆钙化醇与肾性骨营养不良。骨骺溶解——抗惊厥治疗。
Arch Dis Child. 1977 Jun;52(6):464-72. doi: 10.1136/adc.52.6.464.
10
Diseases of the urinary system. renal osteodystrophy.泌尿系统疾病。肾性骨营养不良。
Br Med J. 1977 Jul 9;2(6079):110-2. doi: 10.1136/bmj.2.6079.110.